EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Group 1 metabotropic glutamate receptors and schizophrenia

Andrea de Bartolomeis, Karen Kathleen Szumlinski

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling · 2012

DOI: 10.1002/wmts.15 ↗
AbstractBibliografische Angaben

Abstract

Abstract Schizophrenia is a prevalent neuropsychiatric disorder associated with perturbations in medial prefrontal cortex (PFC) excitability and connectivity. As such, research into the neurobiology of schizophrenia and related psychotic disorders has focused on understanding the possible role played by the major excitatory neurotransmitter glutamate in mediating the cognitive and psychosocial impairments characteristic of this disease. Historically, the ionotropic NMDA glutamate receptor has received the greatest experimental attention in this regard. However, converging data point to Group 1 metabotropic glutamate receptors (mGluRs), as well as the Group 1 mGluR scaffolding protein Homer, as critical for normal psychomotor and cognitive function. Moreover, data derived primarily from behavioral pharmacological and genetic studies conducted in animal models of psychosis, suggest that dysregulation of Group 1 mGluR signaling may contribute to anomalies in neuronal excitation putatively underpinning the manifestation of cognitive abnormalities and psychotic‐like behavior. These data implicate targeting Group 1 mGluRs as viable pharmacotherapeutic strategies for the treatment of schizophrenia and related disorders. WIREs Membr Transp Signal 2012, 1:94–103. doi: 10.1002/wmts.15 For further resources related to this article, please visit the WIREs website .

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →